Terms: = Brain cancer AND NTRK3, TRKC, 4916, ENSG00000140538, Q16288, gp145 trkC AND Treatment
39 results:
1. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.
El-Nassan HB; Al-Qadhi MA
Eur J Med Chem; 2023 Oct; 258():115618. PubMed ID: 37413881
[TBL] [Abstract] [Full Text] [Related]
2. Larotrectinib Response in ntrk3 Fusion-Driven Diffuse High-Grade Glioma.
König D; Hench J; Frank S; Dima L; Bratic Hench I; Läubli H
Pharmacology; 2022; 107(7-8):433-438. PubMed ID: 35526519
[TBL] [Abstract] [Full Text] [Related]
3. LINC02381-ceRNA exerts its oncogenic effect through regulation of IGF1R signaling pathway in glioma.
Nemati H; Fakhre-Taha M; Javanmard AR; Jahanbakhshi A; Mowla SJ; Soltani BM
J Neurooncol; 2022 May; 158(1):1-13. PubMed ID: 35460500
[TBL] [Abstract] [Full Text] [Related]
4. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract] [Full Text] [Related]
5. Case of multifocal glioblastoma with four fusion transcripts of
Samii A; Sorokin M; Kar S; Makovskaia L; Garazha A; Hartmann C; Moisseev A; Kim E; Giese A; Buzdin A
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34341009
[TBL] [Abstract] [Full Text] [Related]
6. Secretory carcinoma of the breast with multiple distant metastases in the brain and unfavorable prognosis: a case report and literature review.
Tang H; Zhong L; Jiang H; Zhang Y; Liang G; Chen G; Xie G
Diagn Pathol; 2021 Jun; 16(1):56. PubMed ID: 34162406
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract] [Full Text] [Related]
8. Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date.
Araujo JM; Gomez AC; Pinto JA; Rolfo C; Raez LE
Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):192-198. PubMed ID: 33290717
[TBL] [Abstract] [Full Text] [Related]
9. Central nervous system ganglioneuroblastoma harboring MYO5A-ntrk3 fusion.
Ito J; Nakano Y; Shima H; Miwa T; Kogure Y; Isshiki K; Yamazaki F; Oishi Y; Morimoto Y; Kataoka K; Okita H; Hirato J; Ichimura K; Shimada H
Brain Tumor Pathol; 2020 Jul; 37(3):105-110. PubMed ID: 32556925
[TBL] [Abstract] [Full Text] [Related]
10. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
[No Abstract] [Full Text] [Related]
11. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract] [Full Text] [Related]
12. Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven cancer.
Tanaka H; Sase H; Tsukaguchi T; Hasegawa M; Tanimura H; Yoshida M; Sakata K; Fujii T; Tachibana Y; Takanashi K; Higashida A; Hasegawa K; Ono Y; Oikawa N; Mio T
Mol Cancer Ther; 2018 Dec; 17(12):2519-2529. PubMed ID: 30242093
[TBL] [Abstract] [Full Text] [Related]
13. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.
Ziegler DS; Wong M; Mayoh C; Kumar A; Tsoli M; Mould E; Tyrrell V; Khuong-Quang DA; Pinese M; Gayevskiy V; Cohn RJ; Lau LMS; Reynolds M; Cox MC; Gifford A; Rodriguez M; Cowley MJ; Ekert PG; Marshall GM; Haber M
Br J Cancer; 2018 Sep; 119(6):693-696. PubMed ID: 30220707
[TBL] [Abstract] [Full Text] [Related]
14. Tropomyosin receptor kinase C (trkc) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response.
Friedrich C; Shalaby T; Oehler C; Pruschy M; Seifert B; Picard D; Remke M; Warmuth-Metz M; Kortmann RD; Rutkowski S; Grotzer MA; von Bueren AO
Childs Nerv Syst; 2017 Sep; 33(9):1463-1471. PubMed ID: 28695340
[TBL] [Abstract] [Full Text] [Related]
15. Autophagy and trkc/NT-3 signaling joined forces boost the hypoxic glioblastoma cell survival.
Jawhari S; Bessette B; Hombourger S; Durand K; Lacroix A; Labrousse F; Jauberteau MO; Ratinaud MH; Verdier M
Carcinogenesis; 2017 Jun; 38(6):592-603. PubMed ID: 28402394
[TBL] [Abstract] [Full Text] [Related]
16. Neurotrophin signaling via TrkB and trkc receptors promotes the growth of brain tumor-initiating cells.
Lawn S; Krishna N; Pisklakova A; Qu X; Fenstermacher DA; Fournier M; Vrionis FD; Tran N; Chan JA; Kenchappa RS; Forsyth PA
J Biol Chem; 2015 Feb; 290(6):3814-24. PubMed ID: 25538243
[TBL] [Abstract] [Full Text] [Related]
17. p75 neurotrophin receptor cleavage by α- and γ-secretases is required for neurotrophin-mediated proliferation of brain tumor-initiating cells.
Forsyth PA; Krishna N; Lawn S; Valadez JG; Qu X; Fenstermacher DA; Fournier M; Potthast L; Chinnaiyan P; Gibney GT; Zeinieh M; Barker PA; Carter BD; Cooper MK; Kenchappa RS
J Biol Chem; 2014 Mar; 289(12):8067-85. PubMed ID: 24519935
[TBL] [Abstract] [Full Text] [Related]
18. Impact of genetic targets on primary brain tumor therapy: what's ready for prime time?
Zalatimo O; Zoccoli CM; Patel A; Weston CL; Glantz M
Adv Exp Med Biol; 2013; 779():267-89. PubMed ID: 23288644
[TBL] [Abstract] [Full Text] [Related]
19. Response of medulloblastoma cells to vincristine and lomustine: role of trkc, CTNNB1 and STK15.
Shinwari Z; Al-Hindi H; Al-Shail E; Khafaga Y; Al-Kofide A; El-Kum N; Aboussekhra A
Anticancer Res; 2011 May; 31(5):1721-33. PubMed ID: 21617231
[TBL] [Abstract] [Full Text] [Related]
20. Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor.
Cazorla M; Arrang JM; Prémont J
Br J Pharmacol; 2011 Feb; 162(4):947-60. PubMed ID: 21039416
[TBL] [Abstract] [Full Text] [Related]
[Next]
